These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 23079299)

  • 41. Reallocating resources: how should the National Institute for Health and Clinical Excellence guide disinvestment efforts in the National Health Service?
    Pearson S; Littlejohns P
    J Health Serv Res Policy; 2007 Jul; 12(3):160-5. PubMed ID: 17716419
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of NICE technology appraisal in NHS rationing.
    Walker S; Palmer S; Sculpher M
    Br Med Bull; 2007; 81-82():51-64. PubMed ID: 17409119
    [TBL] [Abstract][Full Text] [Related]  

  • 44. NICE's use of cost effectiveness as an exemplar of a deliberative process.
    Culyer AJ
    Health Econ Policy Law; 2006 Jul; 1(Pt 3):299-318. PubMed ID: 18634698
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Eliciting stated preferences for health-technology adoption criteria using paired comparisons and recommendation judgments.
    Johnson FR; Backhouse M
    Value Health; 2006; 9(5):303-11. PubMed ID: 16961548
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bridging the gap between methods research and the needs of policy makers: a review of the research priorities of the National Institute for Health and Clinical Excellence.
    Longworth L; Sculpher MJ; Bojke L; Tosh JC
    Int J Technol Assess Health Care; 2011 Apr; 27(2):180-7. PubMed ID: 21447260
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evidence-informed evidence-making.
    Chalkidou K; Walley T; Culyer A; Littlejohns P; Hoy A
    J Health Serv Res Policy; 2008 Jul; 13(3):167-73. PubMed ID: 18573766
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The ethics of grandfather clauses in healthcare resource allocation.
    Wester G; Gibson Rand LZ; Lu C; Sheehan M
    Bioethics; 2021 Feb; 35(2):151-160. PubMed ID: 33043477
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals.
    Bryan S; Williams I; McIver S
    Health Econ; 2007 Feb; 16(2):179-93. PubMed ID: 16960851
    [TBL] [Abstract][Full Text] [Related]  

  • 50. NICE guidance in the Scottish context.
    Kohli H; Tannahill A
    Scott Med J; 2009 Feb; 54(1):35-8. PubMed ID: 19291935
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Getting their say, or getting their way? Has participation strengthened the patient "voice" in the National Institute for Clinical Excellence?
    Quennell P
    J Manag Med; 2001; 15(3):202-19. PubMed ID: 11547580
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A determination of topics for health technology assessment in Thailand: making decision makers involved.
    Lertpitakpong C; Chaikledkaew U; Thavorncharoensap M; Tantivess S; Praditsitthikorn N; Youngkong S; Yothasamut J; Udomsuk K; Sinthitichai K; Teerawattananon Y
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S100-9. PubMed ID: 19253492
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Health economic evaluation in England.
    Raftery J
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):367-74. PubMed ID: 25444294
    [TBL] [Abstract][Full Text] [Related]  

  • 54. NICE's selective application of differential discounting: ambiguous, inconsistent, and unjustified.
    O'Mahony JF; Paulden M
    Value Health; 2014 Jul; 17(5):493-6. PubMed ID: 25128041
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Evolving Nature of Health Technology Assessment: A Critical Appraisal of NICE's New Methods Manual.
    Angelis A; Harker M; Cairns J; Seo MK; Legood R; Miners A; Wiseman V; Chalkidou K; Grieve R; Briggs A
    Value Health; 2023 Oct; 26(10):1503-1509. PubMed ID: 37268059
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 10 years of NICE: still growing and still controversial.
    Littlejohns P; Garner S; Doyle N; Macbeth F; Barnett D; Longson C
    Lancet Oncol; 2009 Apr; 10(4):417-24. PubMed ID: 19341973
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The National Institute for Health and Clinical Excellence and its role in assessing the value of new cancer treatments in England and Wales.
    Trowman R; Chung H; Longson C; Littlejohns P; Clark P
    Clin Cancer Res; 2011 Aug; 17(15):4930-5. PubMed ID: 21791636
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Representation and legitimacy in health policy formulation at a national level: perspectives from a study of health technology eligibility procedures in the United Kingdom.
    Milewa T
    Health Policy; 2008 Mar; 85(3):356-62. PubMed ID: 17936401
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The normative grounds for NICE decision-making: a narrative cross-disciplinary review of empirical studies.
    Charlton V
    Health Econ Policy Law; 2022 Oct; 17(4):444-470. PubMed ID: 35293306
    [TBL] [Abstract][Full Text] [Related]  

  • 60. NICE technology appraisals: working with multiple levels of uncertainty and the potential for bias.
    Brown P; Calnan M
    Med Health Care Philos; 2013 May; 16(2):281-93. PubMed ID: 22198480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.